AACR Cancer Progress Report 2026 Links Patient Stories to New Therapies Including Zongertinib and ONC201

AACR has released its Cancer Progress Report 2026, built around survivor narratives that trace journeys from diagnosis through clinical trials to treatment with new targeted therapies such as zongertinib and ONC201. The report frames sustained, stable federal research funding as central to rising cancer survival rates, and points to personalized vaccines and new targeted drugs as practice-changing. It includes one forward-looking mention of AI reducing complex data to better starting points for diagnosis and therapy.